Medical Economics November 8, 2024
Key Takeaways
- Trump’s administration may attempt to repeal the Affordable Care Act and the Inflation Reduction Act, affecting drug pricing.
- Robert F. Kennedy Jr.’s potential role in health policy introduces uncertainty, especially regarding vaccine skepticism.
- Industry leaders stress the importance of the FDA’s science-based, patient safety-focused standards.
- The US healthcare system struggles with high costs and modest health outcomes compared to other countries.
A panel at the Financial Times’ 2024 Global Pharma and Biotech Summit in London analyzed what the re-election of Trump could mean to the pharmaceutical industry.
Donald Trump’s victory in the 2024 US presidential election is sure to have an impact on the pharmaceutical industry. During a panel at the Financial Times’ 2024 Global Pharma...
Today's Sponsors
Today's Sponsor